data

Clinical investigators are currently exploring ustekinumab, an IL-12 and IL-23 antagonist, for graft vs host disease (GVHD) prophylaxis in matched unrelated donor hematopoietic cell transplantation (HCT) recipients. A phase 2 …

At the American Society of Nephrology Kidney Week 2025, late-breaking results from the phase 2 BESTOW trial offered updates in transplant immunosuppression. The study evaluated tegoprubart, an investigational anti-CD40L monoclonal …

The study shows consistent results for IMDX's digital PCR-based test kits using IMDX's flagship technology and commercially available DD-CFDNA test kits and NGS kits, as well as 96 implant patients. …

Credit: Unsplash/CC0 Public Domain Artificial intelligence can help doctors better assess the complex factors that influence patient outcomes, researchers announced today at the International Society for Heart and Lung Transplantation …

TFF Pharma Co., Ltd. Oral Presentation Presenting Latest Data from a Phase 2 Study Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC FORT WORTH, Texas, March 25, …